'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.

about

'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.

Item

http://www.wikidata.org/entity/Q48205014

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.

@en

'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.

@nl

type

Item

label

'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.

@en

'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.

@nl

prefLabel

'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.

@en

'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.

@nl

P1476

'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma

@en

P2093

Anne-Marie Watson

http://www.w3.org/2001/XMLSchema#string

Anthony Dodds

http://www.w3.org/2001/XMLSchema#string

Bradley Auguston

http://www.w3.org/2001/XMLSchema#string

Cindy Lee

http://www.w3.org/2001/XMLSchema#string

Fiona Kwok

http://www.w3.org/2001/XMLSchema#string

Hang Quach

http://www.w3.org/2001/XMLSchema#string

John Taper

http://www.w3.org/2001/XMLSchema#string

Kerry Taylor

http://www.w3.org/2001/XMLSchema#string

Kirk Morris

http://www.w3.org/2001/XMLSchema#string

Nicholas Weber

http://www.w3.org/2001/XMLSchema#string

P2860

Risk of selection bias in randomised trials

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.

International staging system for multiple myeloma.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function

Pomalidomide.

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.

International Myeloma Working Group recommendations for global myeloma care.

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

P304

1514-1516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1387911

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29022836

http://www.w3.org/2001/XMLSchema#string